«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

28卷

期数:

2022年01期

页码:

15-19

栏目:

生物信息学专题

出版日期:

2022-01-20

文章信息/Info

Title:

The expression and clinical significance of JMJD6 in hepatocellular carcinoma based on TCGA database

文章编号:

1006-8147（2022）01-0015-05

作者:

赵冉; 武燕洁; 刘振凤; 冯圣鋆; 兰蓓

（天津医科大学基础医学院生物化学与分子生物学系，天津 300070）

Author(s):

ZHAO Ran; WU Yan-jie; LIU Zhen-feng; FENG Sheng-yun; LAN Bei

（Department of Biochemistry and Molecular Biology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China）

关键词:

TCGA; 肝癌; JMJD6; 预后分析

Keywords:

TCGA; hepatocellular carcinoma; JMJD6; prognosis analysis

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：分析JMJD6在肝癌中的表达及与预后的关系。方法：从TCGA数据库中下载肝癌患者的mRNA表达数据及患者临床信息。利用Wilcoxon检验比较肝癌组织和正常组织中JMJD6的表达差异，单因素Logistic回归分析JMJD6表达量与临床特征的关系。通过Kaplan-Meier法和Cox回归分析JMJD6表达量与患者生存率的关系。将肝癌组织分成JMJD6高表达组和低表达组并进行基因集富集分析（GSEA）。结果：与正常组织相比，JMJD6在肝癌组织中高表达（W=2 506，P＜0.001），且表达量与临床分期和病理分级相关（均P＜0.05）。JMJD6高表达导致患者生存率下降（χ2=5.541，P＜0.05），并且是肝癌患者预后的独立危险因素（HR=1.109，95% CI： 1.039~1.184，P＜0.01）。此外，GSEA结果显示JMJD6高表达组在DNA复制、RNA剪接等通路富集，低表达组在脂肪酸和氨基酸代谢通路富集。结论：JMJD6高表达与肝癌的发生、发展及患者不良预后相关。

Abstract:

Objective：To analyze the expression of JMJD6 in hepatocellular carcinoma（HCC） and its relationship with prognosis. Methods：The mRNA expression data and clinical information of patients with HCC were downloaded from The Cancer Genome Atlas（TCGA） database. The expression of JMJD6 in HCC tissues and normal tissues was compared by Wilcoxon Test，and univariate Logistic regression analysis was used to analyze the relationship between JMJD6 expression and clinical features. The relationship between JMJD6 expression and patient survival was analyzed by Kaplan-Meier method and Cox regression analysis. Gene set enrichment analysis（GSEA） was performed in the high and low expression groups of JMJD6. Results： Compared with normal tissues，the expression of JMJD6 was up-regulated in HCC tissues（Wilcoxon test，W=2 506，P＜0.001） and the expression level was correlated with clinical stage and pathological grade （all P＜0.05）. The high expression of JMJD6 was related to adverse prognosis of HCC（χ2=5.541，P＜0.05），and the expression of JMJD6 could be an independent factor affecting the survival of patients （HR=1.109，95%CI：1.039-1.184，P＜0.01）. In addition，GSEA results showed that JMJD6 high expression group was enriched in DNA replication and RNA splicing pathways，while JMJD6 low expression group was enriched in fatty acid and amino acid metabolism pathways. Conclusion： The high expression of JMJD6 is associated with the occurrence and development of HCC and the adverse prognosis of patients.

参考文献/References:

[1] LIU Y，LONG Y H，WANG S Q，et al. JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity[J]. Oncogene，2019， 38（7）：980-997.
[2] CHANG B，CHEN Y，ZHAO Y，et al. JMJD6 is a histone arginine demethylase[J]. Science，2007，318（5849）：444-447.
[3] LIU W，MA Q，WONG K，et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release[J]. Cell，2013，155（7）：1581-1595.
[4] WEBBY C J，WOLF A，GROMAK N，et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65，a protein associated with RNA splicing[J]. Science，2009，325（5936）：90-93.
[5] LEE Y F，MILLER L D，CHAN X B，et al. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer[J]. Breast Cancer Res，2012，14（3）：R85.
[6] ZHANG J，NI S S，ZHAO W L，et al. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma[J]. Tumour Biol，2013，34（4）：2397-2401.
[7] ZHENG H，TIE Y，FANG Z，et al. Jumonji domain-containing 6 （JMJD6） identified as a potential therapeutic target in ovarian cancer[J]. Signal Transduct Target Ther，2019，4：24.
[8] LIU X，SI W，LIU X，et al. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1，a key MAPK signaling component[J]. Mol Cancer，2017，16（1）：175.
[9] MILLER T E，LIAU B B，WALLACE L C，et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma[J]. Nature，2017，547（7663）：355-359.
[10] DAOUDAKI M，FOUZAS I. Hepatocellular carcinoma[J]. Wien Med Wochenschr，2014，164（21/22）：450-455.
[11] WANG F，HE L，HUANGYANG P，et al. JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation[J]. PLoS Biol，2014，12（3）：e1001819.
[12] GAO W W，XIAO R Q，ZHANG W J，et al. JMJD6 licenses ERalpha-dependent enhancer and coding gene activation by modulating the recruitment of the CARM1/MED12 co-activator complex[J]. Mol Cell，2018，70（2）：340-357.
[13] WILLIAMS G H，STOEBER K. The cell cycle and cancer[J]. J Pathol，2012，226（2）：352-364.
[14] VERMEULEN K，VAN BOCKSTAELE D R，BERNEMAN Z N. The cell cycle： a review of regulation，deregulation and therapeutic targets in cancer[J]. Cell Prolif，2003，36（3）：131-149.
[15] LEI Y，WANG S，LIU J，et al. Identification of MCM family as potential therapeutic and prognostic targets for hepatocellular carcinoma based on bioinformatics and experiments[J]. Life Sci，2021，272：119227.

相似文献/References:

[1]陈 环.肝癌介入治疗前后α2-抗纤溶酶、抗凝血酶Ⅲ、凝血因子Ⅷ检测的临床意义[J].天津医科大学学报,2014,20(04):327.
[2]廖诗晗,赵秀兰,张艳辉,等.LCMT1在肝癌中的表达和预后的意义[J].天津医科大学学报,2019,25(03):246.
　LIAO Shi-han,ZHAO Xiu-lan,ZHANG Yan-hui,et al.The expression and prognostic significance of LCMT1 in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2019,25(01):246.
[3]张丽梅,贾莉莉 综 述,喻文立 审 校.外泌体在病毒性肝炎、肝硬化和肝癌中的作用研究进展[J].天津医科大学学报,2019,25(03):305.
[4]胡善雷,李广明,任 娜,等.GP73在HBV相关性肝病中的水平及意义[J].天津医科大学学报,2019,25(06):615.
　HU Shan-lei,LI Guang-ming,REN Na,et al.The level and significance of GP73 in HBV related liver diseases[J].Journal of Tianjin Medical University,2019,25(01):615.
[5]陈莹,张雅敏.围手术期肠内、外营养治疗在肝切除术后患者快速康复中的作用[J].天津医科大学学报,2021,27(04):384.
　CHEN Ying,ZHANG Ya-min.Effect of perioperative enteral and parenteral nutrition on rapid recovery of patients after hepatectomy[J].Journal of Tianjin Medical University,2021,27(01):384.
[6]谢永丽,汤华.YTHDF1对HBV蛋白表达和HBsAg和HBeAg抗原分泌的作用[J].天津医科大学学报,2021,27(05):461.
　XIE Yong-li,TANG Hua.Role of YTHDF1 on HBV protein expression and secretion of HBsAg and HBeAg antigens[J].Journal of Tianjin Medical University,2021,27(01):461.
[7]闫墨,刘帅兵,王楷斌,等.基于生物信息学方法筛选精原细胞瘤进展中的脂代谢关键基因[J].天津医科大学学报,2022,28(06):585.
　YAN Mo,LIU Shuai-bing,WANG Kai-bin,et al.Identification of key lipid metabolism genes in the progress of seminoma by integrated bioinformatics analysis[J].Journal of Tianjin Medical University,2022,28(01):585.
[8]罗焱瑞,赵倩.基于多组学Lasso回归分析构建肝癌预测模型[J].天津医科大学学报,2024,30(03):205.[doi:10.20135/j.issn.1006-8147.2024.03.0205]
　LUO Yanrui,ZHAO Qian.A liver cancer prediction model based on multi-omics Lasso regression analysis[J].Journal of Tianjin Medical University,2024,30(01):205.[doi:10.20135/j.issn.1006-8147.2024.03.0205]
[9]武燕洁,李譞媛,宣成昊,等.利用TCGA数据库分析MED19基因在肝癌中的表达及临床意义[J].天津医科大学学报,2022,28(04):383.
　WU Yan-jie,LI Xuan-yuan,XUAN Cheng-hao,et al.Analyze the expression and clinical significance of MED19 gene in hepatocellular carcinoma based on TCGA database[J].Journal of Tianjin Medical University,2022,28(01):383.

备注/Memo

备注/Memo:

基金项目 天津市教委科研计划项目（2018KJ068）
作者简介 赵冉（1996-），女，硕士在读，研究方向：肿瘤表观遗传学；通信作者：兰蓓，E-mail：lanpei@tmu.edu.cn。

常用功能

更新日期/Last Update: 2022-01-20